Alemtuzumab and DHAP (A-DHAP) is effective for relapsed peripheral T-cell lymphoma, unspecified: interim results of a phase II prospective study.
Kim
S J
SJ
Kim
K
K
Kim
B S
BS
Suh
C
C
Huh
J
J
Ko
Y H
YH
Kim
W S
WS
D000328:Adult; D000074323:Alemtuzumab; D000740:Anemia / Q000139:chemically induced; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000627:therapeutic use; D003561:Cytarabine / Q000627:therapeutic use; D003907:Dexamethasone / Q000627:therapeutic use; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008137:Longitudinal Studies; D016399:Lymphoma, T-Cell / Q000188:drug therapy*; D016411:Lymphoma, T-Cell, Peripheral / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012008:Recurrence; D016879:Salvage Therapy; D016019:Survival Analysis; D013601:T-Lymphocytes / Q000187:drug effects; D013921:Thrombocytopenia / Q000139:chemically induced; D016896:Treatment Outcome; D055815:Young Adult
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D003561:Cytarabine; D000074323:Alemtuzumab; D003907:Dexamethasone; D002945:Cisplatin